Skip to content

Read More

The art of the possible: Charlie Hurt on the Trump-Musk cosmic bromance

Advertisement

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles, blue, within neurons, harming synaptic communication between nerve cells. An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday, Nov. 29, 2022 — and the next question is how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments. (National Institute on Aging, NIH via AP)

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles, blue, within neurons, harming synaptic communication between nerve cells. An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday, Nov. 29, 2022 — and the next question is how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments. (National Institute on Aging, NIH via AP)

Featured Photo Galleries